HLTH 5063 Module 1 Infectious Disease Biology and Transmission Analysis Example

A Virus That Waits: The Biology and Transmission of Hepatitis B and Why Age at Infection Decides So Much

Student Name

American College of Education

HLTH5063: Biology and Disease Risk in Human Health

Module 1 Assignment

Instructor Name

October 5, 2026

Why Hepatitis B

Hepatitis B is a vaccine-preventable infection that still leaves large numbers of people in the United States with a chronic disease most of them do not know they have. CDC's 2023 screening recommendations noted estimates that about 0.42 million people born in the United States and about 1.47 million people born elsewhere were living with chronic hepatitis B, and that national goals call for raising the share who know about their infection from about 32% to 90% by 2030 (Conners et al., 2023). The infection is concentrated among people born in regions where it is common, including East and Southeast Asia, parts of Africa and the Caribbean.

This paper explains the biology and transmission of hepatitis B virus as a foundation for a composite county health department's prevention work. The county is home to large communities of immigrants from Vietnam, the Philippines and West Africa. Understanding how the virus behaves explains why so many infections are silent, why age at infection matters so much, and why the tools of prevention look the way they do.

The Virus

Hepatitis B virus is a small, enveloped DNA virus that infects liver cells. After entering a liver cell, its genome is converted in the nucleus into a stable circular form that serves as a template for making new virus. That persistent genetic reservoir is one reason chronic infection is so hard to eliminate: antiviral drugs can suppress replication for years, but they rarely clear the reservoir, which is why treatment is described as controlling rather than curing the infection. The virus itself does not usually kill liver cells directly. Much of the liver damage in hepatitis B comes from the body's immune response attacking infected cells, which means that the course of disease depends heavily on the host as well as the virus.

The virus produces several markers that laboratories use to track infection. Hepatitis B surface antigen in the blood indicates current infection; antibody to the surface antigen indicates immunity from recovery or vaccination; and antibody to the core antigen indicates past or current infection. Those three markers form the basis of the screening panel discussed later in this course.

How It Spreads

Hepatitis B spreads through percutaneous or mucosal exposure to infectious blood or body fluids. The virus is highly infectious, can be transmitted without visible blood, and remains viable on environmental surfaces for at least seven days (Schillie et al., 2018). The main routes are sexual contact, sharing needles or other drug equipment, exposure to blood in health care or household settings, such as shared razors or toothbrushes, and transmission from an infected mother to her baby, usually during delivery. Persons with chronic infection are the main reservoir for transmission.

Transmission patterns differ around the world, and those differences explain the county's burden. Where the virus is common, as in much of East and Southeast Asia and sub-Saharan Africa, most infections historically occurred at birth or in early childhood, through mothers and household contacts. Where it is less common, as in the United States, most new infections occur in adults through sex and drug use. People who were infected as infants in their countries of birth now make up most of the chronic infections in the county.

Incubation and Clinical Course

After exposure, the average incubation period is about 60 days to abnormal liver enzymes and about 90 days to jaundice. Infants, young children and adults with weakened immune systems who are newly infected usually have no symptoms, whereas about 30% to 50% of older children, adolescents and adults develop symptoms such as nausea, abdominal pain, fever, dark urine and jaundice (Schillie et al., 2018). Most healthy adults clear the infection. Those who do not develop chronic infection, which can progress over decades to cirrhosis, liver failure and liver cancer. National recommendations note that about a quarter of people who become chronically infected in childhood, and about 15% of those infected later, will die prematurely from cirrhosis or liver cancer (Schillie et al., 2018).

Why Age at Infection Decides So Much

The single most important biological fact for prevention is the relationship between age at infection and chronic infection. Edmunds et al. (1993), analyzing data from many surveys, found a remarkably consistent pattern: infants infected in the first six months of life had a probability of becoming chronic carriers of about 0.89, the proportion fell sharply through early childhood, and by adulthood, over 15 years, it was about 0.1. The likely explanation is immunological. A newborn's immune system tends to tolerate the virus rather than attack it, which prevents early liver damage but allows the infection to persist.

This relationship has two consequences. First, it explains why most chronic infections worldwide began at birth or in early childhood, often silently. Second, as Edmunds and colleagues noted, it means that preventing infection in infancy and early childhood has a disproportionately large effect on the number of new chronic carriers. Protecting a newborn from hepatitis B prevents not just one infection but, very likely, a lifetime of chronic disease.

What the Biology Means for the County

Each biological feature points to a public health action. Because chronic infection is usually silent, the county cannot rely on symptoms to find it; testing is essential, especially among adults born in regions where the virus is common. Because the virus spreads efficiently through blood and from mother to baby, prenatal testing and prompt protection of infants born to infected mothers are critical. Because infection in infancy almost always becomes chronic, vaccination early in life has outsized benefits. And because the virus persists in liver cells and damage accumulates over decades, people found to be chronically infected need ongoing medical care and monitoring for liver cancer, not a single visit. The county's current approach, which relies mainly on clinicians to test people they judge to be at risk, misses many of those infected, because the people most likely to carry the virus were infected as children elsewhere and feel well.

Household Contacts and Stigma

Two further features of the biology shape how the county should approach communities. Because the virus spreads within households through blood and close contact, the family members of a person with chronic infection are at risk and should be tested and, if not immune, vaccinated. Because chronic infection is silent and often discovered only by testing, a diagnosis can come as a shock and carry stigma, particularly in communities where hepatitis B is associated with fears about marriage, employment or contagion. Accurate information about how the virus does and does not spread, for example that it is not spread by sharing meals, hugging or casual contact, is part of prevention. The county's outreach will need to explain the biology clearly in Vietnamese, Tagalog, French and other languages, working through community organizations and health workers who can address those fears directly.

References

Conners, E. E., Panagiotakopoulos, L., Hofmeister, M. G., Spradling, P. R., Hagan, L. M., Harris, A. M., Rogers-Brown, J. S., Wester, C., & Nelson, N. P. (2023). Screening and testing for hepatitis B virus infection: CDC recommendations, United States, 2023. MMWR Recommendations and Reports, 72(1), 1-25. https://doi.org/10.15585/mmwr.rr7201a1

Edmunds, W. J., Medley, G. F., Nokes, D. J., Hall, A. J., & Whittle, H. C. (1993). The influence of age on the development of the hepatitis B carrier state. Proceedings of the Royal Society of London. Series B: Biological Sciences, 253(1337), 197-201. https://doi.org/10.1098/rspb.1993.0102

Schillie, S., Vellozzi, C., Reingold, A., Harris, A., Haber, P., Ward, J. W., & Nelson, N. P. (2018). Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and Reports, 67(1), 1-31. https://doi.org/10.15585/mmwr.rr6701a1